Concerns About Randomized Controlled Trials
Introduction to Randomization
Despite being widely regarded as the gold standard in clinical research, a recent publication in the Annals of Medicine raises questions about the objectivity of randomized controlled trials (RCTs). Randomization is a crucial component of modern clinical studies, involving the random allocation of participants to either the experimental group or the control group. This process aims to eliminate bias, but Alexander Krauss, a fellow in scientific methods at the London School of Economics, has published findings that suggest randomization alone may not be sufficient.
Analysis of Frequently Cited Trials
Krauss’s investigation focused on the ten most commonly cited randomized controlled trials, each with at least 6,500 citations. His research highlights potential biases that may not have been previously acknowledged or reported. The findings were published in the Annals of Medicine and summarized in a report by the BMJ.
Questionable Significance of Findings
One notable example from Krauss’s analysis involves a 1995 trial that evaluated the effectiveness of a clot-busting drug for treating ischemic stroke. Although the trial indicated that the treatment group was 3% less likely to develop congestive heart failure compared to the control group, the observed differences were minimal. The treatment group’s chance of dying within three months was only 4% different from that of the placebo group.
Krauss argues that to confidently attribute observed differences to the treatment rather than chance, randomization must create evenly distributed participant characteristics. He contends that if the trial were to be re-randomized multiple times, the outcomes would likely differ, suggesting that the result is merely a consequence of a single randomization.
Examining Potential Biases
Krauss outlines several potential biases present in randomized controlled trials:
– **Sample Selection Bias**: This bias can occur when participants are recruited from a limited geographical area or from various international centers without sufficient information about the patient populations or the treating physicians.
– **Lack of Blinding Bias**: In one trial examining cholesterol-lowering drugs, participants, despite being randomly assigned to treatment or placebo, independently discovered their cholesterol levels and opted to take treatments instead of the placebo.
– **Quantitative Variable Limitations**: RCTs often require primary outcomes that are easily comparable between groups, such as mortality rates. For instance, a colorectal cancer trial showed that while the treatment group survived an average of 4.5 months longer, their quality of life significantly decreased, with increased occurrences of adverse reactions and high blood pressure.
Krauss argues that despite the longer survival of the treatment group, the decline in quality of life may lead patients to prefer not receiving treatment.
Recommendations for Improving RCTs
While Krauss acknowledges the importance of randomized controlled trials in guiding physician and scientific decision-making, he cautions that no single study should be viewed as definitive. To mitigate potential biases in future RCTs, he proposes enhancements to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.
One recommendation includes the requirement of reporting patient data at the conclusion of the study, rather than only at the start. This approach addresses the assumption that participant characteristics remain static throughout the trial. Additionally, Krauss suggests that journals mandate a dedicated section from researchers discussing their assumptions, biases, and limitations in their studies.
Conclusion
Krauss’s findings serve as a reminder of the complexities associated with randomized controlled trials and the need for ongoing scrutiny and improvement to ensure their reliability in clinical research.
Reference
Hawkes, Nigel. Randomised controlled trials may have many unrecognized potential biases. The BMJ website https://www.bmj.com/content/361/bmj.k1561. Accessed April 18th, 2018.